← Back to Clinical Trials
Recruiting NCT07138677

NCT07138677 Safty and Efficacy of MCI Network Guided TMS for Early Alzheimer's Disease: A Randomized, Double-blind Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07138677
Status Recruiting
Phase
Sponsor Anhui Medical University
Condition Alzheimer's Disease
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2025-07-20
Primary Completion 2025-12-30

Eligibility & Interventions

Sex All sexes
Min Age 45 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
transcranial magnetic stimulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2025-07-20 with a primary completion date of 2025-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Estimate the safty and efficacy of personalized network neuronavigated transcranial magnetic stimulations in early Alzheimer's disease patients

Eligibility Criteria

Inclusion Criteria: 1. Subject diagnosed as either mild cognitive impairment due to AD or mild AD dementia based on National Institute on Aging-Alzheimer's Association criteria. 2. MMSE score 18-28. 3. CDR score 0.5-1. 4. On stable treatment with IAChE or memantine for at least 6 months. 5. Literate in Han Chinese. Exclusion Criteria: 1. Recevied rTMS treatment in the past 3 months. 2. Depression or other psychiatric disorders. 3. History of head injury, stroke, epilepsy or other neurologic disease. 4. Organic brain defects on T1 or T2 images. 5. History of unexplained loss of consciousness. 6. Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, or any implanted medical device that is incompatible with MRI. 7. Family history of medication refractory epilepsy. 8. History of substance abuse within the last 6 months.

Contact & Investigator

Central Contact

Kai Wang, PhD

✉ wangkai1964@126.com

📞 +86-0551-62922263

Frequently Asked Questions

Who can join the NCT07138677 clinical trial?

This trial is open to participants of all sexes, aged 45 Years or older, up to 85 Years, studying Alzheimer's Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07138677 currently recruiting?

Yes, NCT07138677 is actively recruiting participants. Contact the research team at wangkai1964@126.com for enrollment information.

Where is the NCT07138677 trial being conducted?

This trial is being conducted at Hefei, China.

Who is sponsoring the NCT07138677 clinical trial?

NCT07138677 is sponsored by Anhui Medical University. The trial plans to enroll 40 participants.

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology